New Study: Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market 2015-2019

CINV is one of the most dreaded adverse effects of chemotherapy. It often leads to the postponement or refusal of potentially curative chemotherapy treatment for cancer. This nausea and vomiting, associated with chemotherapy regimen, affects the quality of life of an individual.

The neurotransmitters in CINV are dopamine, 5-HT3, substance P, and endocannabinoids. CINV can be caused by the stimulation of vomiting center by the abdominal vagal afferents or by the direct stimulation of CTZ in the area postrema. The risk of development of CINV changes with the use of different types of chemotherapy regimens such as high, moderate, low, and minimal risk.

Based on the type of CINV, different treatment regimens are prescribed. The classes of drugs used in the treatment of CINV are 5-HT3 receptor antagonists, NK1 receptor antagonists, corticosteroids, dopamine antagonists, benzodiazepines, and cannabinoids. Most of the drugs used in the treatment are helpful in the prevention of vomiting but show less effect in treating nausea.

Technavio's analysts forecast the global chemotherapy induced nausea and vomiting drugs market to grow at a CAGR of 4.9% over the period 2014-2019.

Commenting on the report, an analyst from Technavio's team said: "One major trend in the market is individuals tend to develop resistance to monotherapies over a period of time, resulting in the increased preference for combination therapies. These combination therapies have a better safety and efficacy profile, increasing their preference for treating CINV."

According to the report, one key driver of this market is patent expiries result in the loss of market exclusivity of a drug, leading to a rapid decline in its sales. This leads to the market entry of generic forms that have a similar efficacy and safety profile as the branded drug and are available at low prices. The patents of most of the CINV drugs have either expired or are set to expire by the end of the forecast period.

Further, the report states that one of the major challenges in the market is off-label drugs are unapproved medications, but show efficacy in the treatment of the condition. Many off-label drugs are used to manage CINV. Corticosteroids, such as dexamethasone, are commonly used to treat CINV.

The key players in the Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market are GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck & Co and Tesaro while other prominent vendors include Acacia Pharma, Aphios, Barr Laboratories, Baxter Healthcare, Eisai, Especificos Stendhal, F.Hoffmann La Roche, Mundipharma, Mylan Pharmaceuticals, OPKO Health, Orchid Healthcare, Otsuka Pharmaceutical, ProStrakan, Sandoz (Novartis), Solvay Pharmaceuticals, Specialised Therapeutics Australia, Sun Pharma, Taiho Pharmaceutical and Teva Pharmaceuticals.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2015
- Post Operative Nausea And Vomiting Global Clinical Trials Review, H1, 2015
- Global Opioid-Induced Constipation Market 2015-2019
- Global Colorectal Cancer Drugs Market 2015-2019
- Global Gastrointestinal OTC Drugs Market 2015-2019